ImmuCell Co. (NASDAQ:ICCC) Sees Significant Increase in Short Interest

ImmuCell Co. (NASDAQ:ICCCGet Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 7,900 shares, an increase of 5.3% from the January 31st total of 7,500 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 8,700 shares, the short-interest ratio is presently 0.9 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ICCC. Dimensional Fund Advisors LP raised its stake in ImmuCell by 175.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 62,170 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 39,591 shares during the last quarter. Vanguard Group Inc. raised its stake in ImmuCell by 22.2% in the 1st quarter. Vanguard Group Inc. now owns 204,325 shares of the biotechnology company’s stock valued at $1,972,000 after purchasing an additional 37,081 shares during the last quarter. Northern Trust Corp raised its stake in ImmuCell by 153.8% in the 4th quarter. Northern Trust Corp now owns 32,646 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 19,781 shares during the last quarter. Mission Wealth Management LP acquired a new position in ImmuCell in the 3rd quarter valued at $53,000. Finally, Geode Capital Management LLC raised its stake in ImmuCell by 20.1% in the 2nd quarter. Geode Capital Management LLC now owns 45,727 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 7,645 shares during the last quarter. 13.67% of the stock is owned by institutional investors and hedge funds.

ImmuCell Trading Down 2.9 %

Shares of NASDAQ:ICCC opened at $5.30 on Wednesday. ImmuCell has a 1 year low of $4.26 and a 1 year high of $6.16. The firm has a market capitalization of $41.08 million, a price-to-earnings ratio of -7.07 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.59 and a quick ratio of 1.37. The business’s 50 day moving average price is $5.12 and its 200-day moving average price is $4.97.

About ImmuCell

(Get Free Report)

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

Featured Stories

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.